Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarMMa-3
2023-509848-10-00Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Idecabtagene vicleucel (Abecma) with Standard-of-care regimens (2 arms). Primary endpoint: Progression-free survival. Started Jun 2024; status: completed.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-509848-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509848-10-00.